Recombinant Human Ras association domain-containing protein 1 (RASSF1)

Code CSB-YP885715HU
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP885715HU
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP885715HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP885715HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP885715HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
RASSF1
Uniprot No.
Alternative Names
123F2; Cardiac specific ras association domain family 1 protein; cardiac-specific ras association domain family 1 protein; 123F2 ; NORE2A; OTTHUMP00000195503; OTTHUMP00000195504; OTTHUMP00000195505; OTTHUMP00000195507; Pancreas specific ras association domain family 1 protein; Ras association (RalGDS/AF 6) domain family member 1; Ras association domain-containing protein 1; RASF1_HUMAN; Rassf1; RASSF1A; RDA32; REH3P21; Tumor suppressor protein RDA32; WUGSC:H_LUCA12.5
Species
Homo sapiens (Human)
Expression Region
2-344
Target Protein Sequence
SGEPELIEL RELAPAGRAG KGRTRLERAN ALRIARGTAC NPTRQLVPGR GHRFQPAGPA THTWCDLCGD FIWGVVRKGL QCARLSADCK FTCHYRCRAL VCLDCCGPRD LGWEPAVERD TNVDEPVEWE TPDLSQAEIE QKIKEYNAQI NSNLFMSLNK DGSYTGFIKV QLKLVRPVSV PSSKKPPSLQ DARRGPGRGT SVRRRTSFYL PKDAVKHLHV LSRTRAREVI EALLRKFLVV DDPRKFALFE RAERHGQVYL RKLLDDEQPL RLRLLAGPSD KALSFVLKEN DSGEVNWDAF SMPELHNFLR ILQREEEEHL RQILQKYSYC RQKIQEALHA CPLG
Protein Length
Full Length of Mature Protein
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Potential tumor suppressor. Required for death receptor-dependent apoptosis. Mediates activation of STK3/MST2 and STK4/MST1 during Fas-induced apoptosis by preventing their dephosphorylation. When associated with MOAP1, promotes BAX conformational change and translocation to mitochondrial membranes in response to TNF and TNFSF10 stimulation. Isoform A interacts with CDC20, an activator of the anaphase-promoting complex, APC, resulting in the inhibition of APC activity and mitotic progression. Inhibits proliferation by negatively regulating cell cycle progression at the level of G1/S-phase transition by regulating accumulation of cyclin D1 protein. Isoform C has been shown not to perform these roles, no function has been identified for this isoform. Isoform A disrupts interactions among MDM2, DAXX and USP7, thus contributing to the efficient activation of TP53 by promoting MDM2 self-ubiquitination in cell-cycle checkpoint control in response to DNA damage.
Gene References into Functions
  1. Tissues from patients with serous and non-serous EOC showed significantly higher promoter methylation of EGFL7 and RASSF1 compared to benign cases. PMID: 29778234
  2. Transcriptome assay unclosed that RASSF1A promoted IL-6 expression in A375 cells, which in turn activate JAK2/STAT3 signaling. PMID: 30074127
  3. Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy. PMID: 27698403
  4. Low RASSF1A expression is associated with gastric cancer. PMID: 30106448
  5. methylation of BRCA1, RASSF1A and GSTP1 was found in 58.23 %, 74.68 % and 59.49 % of tumor tissues and 51.90 %, 63.29 % and 35.44 % of corresponding adjacent tissues, respectively PMID: 30049201
  6. Our study established that RASSF1A hypermethylation might have a potential value in the clinical diagnosis of colorectal cancer PMID: 30082160
  7. Effect of decitabine pretreatment on sensitivity of bladder cancer cells towards chemotherapeutic drugs was also studied. Decitabine treatment leads to restoration of RASSF1A, activation of hippo pathway followed by decreased expression of its oncogenic downstream targets (CTGF & CYR61). PMID: 29368096
  8. the use of RASSF1A promoter methylation could distinguish ovarian cancer and low malignant potential tumors. -RASSF1A promoter methylation may not be correlated with the clinical features and the survival of ovarian cancer patients. PMID: 29130987
  9. the methylation positive rates of SHOX2 with RASSF1A in stage III were both higher than the other stages of lung cancer PMID: 28325362
  10. Tested if RASSF1A polymorphisms associated with ovarian cancer and with tumor grade and stage. Five tagging single nucleotide polymorphisms (SNPs) (rs4688728G>T, rs72932987C>T, rs1989839C>T, rs2073497A>C, and rs2236947A>C) were evaluated. The CT genotype of rs1989839 was associated with the patients with ovarian cancer (P=0.001), and was significantly correlated with tumor grade and stage (P=0.008). PMID: 29670073
  11. No significant differences were presented in DNA methylation levels of RASSF1A and ATM between the sporadic breast cancer cases and the healthy controls. PMID: 29562656
  12. High Promoter Methylation of RASSF1A gene is associated with Breast Cancer. PMID: 29480000
  13. Hypermethylation of RASSF1 gene is associated with neuroendocrine tumors. PMID: 29851970
  14. The present work proved that there was a higher frequency of RASSF1A methylation and a decrease in its serum level in patients with ovarian cancer compared to controls as well as in the high-grade tumor patients compared to low grade ones and also in advanced ovarian tumor stage compared to early stages. PMID: 29098560
  15. Promoter methylation of RASSF1A can influence sensitivity to oxaliplatin-based chemotherapy, which can be used to predict outcomes for patients with stage II and III Colorectal Cancer PMID: 29128865
  16. The meta-analysis indicates a role of the RASSF1A promoter hypermethylation from peripheral blood in testicular germ cell tumors. PMID: 28871003
  17. RASSF1A is a tumour suppressor gene epigenetically dysregulated in NET. Aberrant methylation of RASSF1A has been reported in various tumours, but this is the first report of RASSF1A hypermethylation in TETs. PMID: 28838380
  18. Study shows that recombinant human bone morphogenetic protein-2 activates hippo signaling through RASSF1 in esophageal cancer cells PMID: 27230238
  19. There were significant associations between RASSF1A promoter hypermethylation and Oral Cancer risk.RASSF1A promoter hypermethylation exerted higher frequency in the Tongue Tumor than other site tumor in mouth. PMID: 29538221
  20. RASSF1A is expressed in differentiating stem cells. PMID: 29382819
  21. Hypermethylation of RASSF1A gene is associated with Colon Cancer. PMID: 26671036
  22. Data show that silencing DNA methyltransferase 1 (DNMT1) increased expression of tumor suppressor genes, RASSF1A and DAPK, in esophageal squamous cell carcinoma (ESCC) cells and ESCC xenograft in nude mice. PMID: 27286455
  23. Describe a novel interaction between Rheb and the tumor suppressor RASSF1A. This interaction may allow coordinate upregulation of Hippo while TOR is suppressed to modulate the balance of apoptosis and autophagy in lung tumor cells. PMID: 27034171
  24. Gestational age-dependent increase of hypermethylated RASSF1A; the fetal specific epigenetic marker in maternal plasma was demonstrated, in an Indian study group of normal pregnant women. PMID: 27165812
  25. the RASSF1 gene polymorphism influences molecular carcinogenesis and clinic pathological features of hepatocellular carcinoma within the Egyptian population PMID: 26921475
  26. We report for the first time that RASSF1A promoter methylation provides significant prognostic information in high-grade serous ovarian cancer patients. PMID: 28206954
  27. The main finding of this study was the significant association between RASSF1A promoter methylation and increased EC risk. PMID: 28669560
  28. Data suggest that the overexpression of DNMT3B4 may play an important role in human kidney tumorigenesis through chromosomal instability and methylation of RASSF1A. PMID: 28160561
  29. Methylation status of the RASSF1A gene promoter was strongly related to melanoma susceptibility but no significant difference was found between RASSF1A gene promoter methylation and the prognosis and clinical-pathological features of melanoma. PMID: 28207831
  30. Our results suggest a multifactorial role of RASSF1A in suppression of liver carcinogenesis PMID: 26980762
  31. rs1989839C/T is an important predictor of osteosarcoma risk and outcome. The CT genotype of rs1989839 is highly related to elevated risk of osteosarcoma. Furthermore, rs1989839C/T is also associated with the Enneking stage of osteosarcoma and risk of lung metastasis. One of the other 4 SNPs, rs2236947A/C, shows a borderline significance in predicting osteosarcoma risk. PMID: 27880743
  32. For the first time, we performed analysis of DNA methylation in SMARCB1/INI1-deficient sinonasal carcinomas, reporting on significantly higher methylation of RASSF1 gene in this neoplasm. PMID: 28069272
  33. High methylation in the RASSF1A promoter region is associated with lung cancer. PMID: 27716889
  34. GSTP1, APC and RASSF1 gene methylation in prostate cancer samples: comparative analysis of MS-HRM method and Infinium HumanMethylation450 BeadChip beadchiparray diagnostic value PMID: 28026816
  35. Compared with adjacent normal tissues, the methylation frequencies of WIF-1, RASSF1A, and CDH13 genes were significantly higher but the mRNA levels of these 3 genes were significantly lower in EC tissues. The survival rates of patients with WIF-1, RASSF1A, and CDH13 methylations were significantly lower than those of patients without methylation PMID: 27506957
  36. The presence of higher RASSF1A methylation levels in fine-needle aspiration cytology specimens of nodular goitre may be useful in the assessment of oncological risk. PMID: 26457492
  37. this meta-analysis demonstrated that RASSF1A promoter methylation is significantly associated with increased risk of renal cell cancer PMID: 27173228
  38. Overexpression of RASSF1A downregulated the cyclin D1. PMID: 26750098
  39. Results show that RASSF1A is involved in colorectal tumorigenesis. Its promotor region is bind to miR-181b stimulating its expression. PMID: 26935905
  40. The meta-analysis suggested that there was a significant association between aberrant RASSF1A methylation and head and neck squamous cell carcinoma. PMID: 26857374
  41. The present meta.analysis provides convincing evidence that the promoter methylation ratio of RASSF1A and p16 is associated with clinicopathological features in lung cancers, and could be used as effective biomarkers in early diagnosis in lung cancers. PMID: 27072261
  42. Loss of RASSF1A is associated with gastric cancer. PMID: 26735582
  43. Different genetic mechanisms seem to contribute to RASSF1 deregulation in this setting, but RASSF1 methylation does not seem to substantially affect RASSF1 isoforms expression. PMID: 26754001
  44. RASSF1C gene is not involved in Clear-cell renal cell carcinoma (ccRCC)progression and we propose that the measurements of RASSF1A mRNA levels in paired tumor-normal kidney tissue could serve as a new prognostic factor in ccRCC PMID: 26648328
  45. Results indicate that hypermethylation of tumor suppressor protein RASSF1A and docking protein 1 (DOK1) contributes to hepatocarcinogenesis and is associated to clinicopathological characteristics. PMID: 27078152
  46. Data indicate tumor suppressors TP73, RASSF1A, MLH1 and BRCA1 as possible biomarkers to distinguish Pleomorphic invasive lobular cancer (pleomorphic ILC} from classic ILC and infiltrative ductal cancer (IDC). PMID: 26392358
  47. Interaction between HPV infection and RASSF1A promoter methylation is associated with the development of cervical cancers. PMID: 26320446
  48. Hypermethylation of RASSF1A gene promoter is associated with esophageal squamous cell carcinoma. PMID: 25886188
  49. RASSF1A promotes the translocation of cytosolic PRMT5 to microtubules.PRMT5 co-localizes with RASSF1A on stabilized microtubules. PMID: 26482848
  50. Tumor-adjacent tissues showed higher methylation status of RASSF1A, HIN-1 and MGMT promoters. PMID: 26370119

Show More

Hide All

Subcellular Location
[Isoform A]: Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle. Cytoplasm, cytoskeleton, spindle pole. Nucleus. Note=Localizes to cytoplasmic microtubules during interphase, to bipolar centrosomes associated with microtubules during prophase, to spindle fibers and spindle poles at metaphase and anaphase, to the midzone during early telophase, and to the midbody in late telophase in cells. Colocalizes with MDM2 in the nucleus.; [Isoform C]: Nucleus. Note=Predominantly nuclear.
Tissue Specificity
Isoform A and isoform C are ubiquitously expressed in all tissues tested, however isoform A is absent in many corresponding cancer cell lines. Isoform B is mainly expressed in hematopoietic cells.
Database Links

HGNC: 9882

OMIM: 605082

KEGG: hsa:11186

STRING: 9606.ENSP00000349547

UniGene: Hs.476270

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1